ROCHELLE RICKMAN: Open Payments
NPI 1457692634 · EVERETT, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,211 in 62 payments from 10 companies in 2025. Trend: 2023 $0 · 2024 $17 · 2025 $1,211
Food & beverage: $995Education: $216
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 9 | $380 |
| Neurocrine BioSciences, Inc. | 17 | $219 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 11 | $187 |
| Alkermes, Inc. | 13 | $142 |
| Otsuka America Pharmaceutical, Inc. | 3 | $71 |
| E.R. Squibb & Sons, L.L.C. | 3 | $63 |
| Vanda Pharmaceuticals Inc. | 2 | $57 |
| Janssen Pharmaceuticals, Inc | 2 | $34 |
| Axsome Therapeutics, Inc. | 1 | $34 |
| ABBVIE INC. | 1 | $24 |
Products named: INGREZZA, CAPLYTA, ARISTADA, AUSTEDO XR, REXULTI, COBENFY, FANAPT, INVEGA SUSTENNA.
Industry payments across WA — which companies pay providers there.
